Balyasny Asset Management’s Adaptimmune Therapeutics ADAP Stock Holding History

Balyasny Asset Management’s Portfolio ADAP Stock Details ADAP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-259,413	Closed	-$1.34M	–	2179
2021 Q3	$1.34M	Buy	+259,413	New	+$1.16M	0.01%	1257
2019 Q1	–	Sell	-567,401	Closed	-$3.26M	–	1371
2018 Q4	$3.26M	Sell	567,401 -414,599	-42%	-$3.06M	0.02%	591
2018 Q3	$13.3M	Buy	982,000 +165,716	+20%	+$1.74M	0.06%	402
2018 Q2	$9.69M	Sell	816,284 -130,784	-14%	-$1.63M	0.04%	498
2018 Q1	$10.6M	Buy	947,068 +224,078	+31%	+$1.96M	0.04%	506
2017 Q4	$4.83M	Buy	722,990 +123,190	+21%	+$951K	0.02%	874
2017 Q3	$4.91M	Buy	599,800 +411,313	+218%	+$2.57M	0.02%	730
2017 Q2	$846K	Buy	+188,487	New	+$985K	﹤0.01%	1148

Other funds holding ADAP

MCMC

Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

LFCM

Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Balyasny Asset Management's ADAP Position: Q4 2021 in Review

Balyasny Asset Management sold out of Adaptimmune Therapeutics (ADAP) in Q4 2021, closing a stake of 259,413 shares — an estimated $1.34M sold.

Balyasny Asset Management first reported a position in ADAP in Q2 2017 and held it in 8 quarters. The position peaked at $13.3M in Q3 2018. 85 funds tracked by Wall St. Rank hold ADAP as of Q4 2021.

Balyasny Asset Management reported no remaining Adaptimmune Therapeutics position as of Q4 2021 after selling out during the quarter.
Balyasny Asset Management sold 259,413 Adaptimmune Therapeutics shares in Q4 2021, an estimated $1.34M.
Balyasny Asset Management first reported a position in Adaptimmune Therapeutics in Q2 2017 and held it in 8 quarters.
Balyasny Asset Management's Adaptimmune Therapeutics position peaked at $13.3M in Q3 2018.
85 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q4 2021.

Based on Balyasny Asset Management's 13F filing for Q4 2021, filed 14 Feb 2022.